BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38287309)

  • 21. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
    Cai F; Zhang Y; Li J; Huang S; Gao R
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
    Yan Y; Huang H
    Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target.
    Gu M; Roy S; Raina K; Agarwal C; Agarwal R
    Cancer Res; 2009 Dec; 69(24):9465-72. PubMed ID: 19920184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline predictors of androgen deprivation therapy response in advanced prostate cancer.
    Kohli M; Riska SM; Mahoney DW; Chai HS; Hillman DW; Rider DN; Costello BA; Qin R; Lamba J; Sahasrabudhe DM; Cerhan JR
    Mayo Clin Proc; 2012 Mar; 87(3):240-6. PubMed ID: 22386179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells.
    Li Q; Huang H; He Z; Sun Y; Tang Y; Shang X; Wang C
    Sci China Life Sci; 2018 May; 61(5):550-558. PubMed ID: 29119376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer.
    Dong Z; Liu Y; Scott KF; Levin L; Gaitonde K; Bracken RB; Burke B; Zhai QJ; Wang J; Oleksowicz L; Lu S
    Carcinogenesis; 2010 Nov; 31(11):1948-55. PubMed ID: 20837598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of Lactate and PD-1-mediated Macrophage Immunosuppression Controls Growth of PTEN/p53-deficient Prostate Cancer.
    Chaudagar K; Hieromnimon HM; Khurana R; Labadie B; Hirz T; Mei S; Hasan R; Shafran J; Kelley A; Apostolov E; Al-Eryani G; Harvey K; Rameshbabu S; Loyd M; Bynoe K; Drovetsky C; Solanki A; Markiewicz E; Zamora M; Fan X; Schürer S; Swarbrick A; Sykes DB; Patnaik A
    Clin Cancer Res; 2023 May; 29(10):1952-1968. PubMed ID: 36862086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
    Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z
    Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer.
    Chen WS; Feng EL; Aggarwal R; Foye A; Beer TM; Alumkal JJ; Gleave M; Chi KN; Reiter RE; Rettig MB; Evans CP; Small EJ; Sharifi N; Zhao SG
    Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):316-323. PubMed ID: 31745256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The PI3K/AKT pathway in the pathogenesis of prostate cancer.
    Chen H; Zhou L; Wu X; Li R; Wen J; Sha J; Wen X
    Front Biosci (Landmark Ed); 2016 Jun; 21(5):1084-91. PubMed ID: 27100493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation modulates gene expression profile along prostate cancer progression.
    Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
    Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.
    Shiota M; Tatarano S; Kamoto T; Matsuyama H; Sakai H; Igawa T; Kamba T; Fujimoto N; Sekine Y; Kimura H; Narita S; Terada N; Momozawa Y; Akamatsu S; Habuchi T; Yokomizo A; Naito S; Eto M
    Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37079309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.
    Harshman LC; Wang X; Nakabayashi M; Xie W; Valenca L; Werner L; Yu Y; Kantoff AM; Sweeney CJ; Mucci LA; Pomerantz M; Lee GS; Kantoff PW
    JAMA Oncol; 2015 Jul; 1(4):495-504. PubMed ID: 26181260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review).
    Toren P; Zoubeidi A
    Int J Oncol; 2014 Nov; 45(5):1793-801. PubMed ID: 25120209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-genomic action of resveratrol on androgen and oestrogen receptors in prostate cancer: modulation of the phosphoinositide 3-kinase pathway.
    Benitez DA; Pozo-Guisado E; Clementi M; Castellón E; Fernandez-Salguero PM
    Br J Cancer; 2007 May; 96(10):1595-604. PubMed ID: 17486135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression.
    Henderson V; Smith B; Burton LJ; Randle D; Morris M; Odero-Marah VA
    Cell Adh Migr; 2015; 9(4):255-64. PubMed ID: 26207671
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Huang SP; Chen LC; Chen YT; Lee CH; Huang CY; Yu CC; Lin VC; Lu TL; Bao BY
    Cancer Genomics Proteomics; 2021; 18(3):325-334. PubMed ID: 33893085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Choudhury AD
    Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.